Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

Journal of Crohn's and Colitis

Volumn 5, Issue 6, 2011, Pages 550-554

  Loftus, Edward V ^a   Pan, Xiaoyun ^b   Zurawski, Pete ^c   Mulani, Parvez ^c   Chao, Jingdong ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Crohn's disease; Pharmacy claims data; Predictors; Weekly dosing

Indexed keywords

ADALIMUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE COMPARISON; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

EID: 80051806028     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.05.005     Document Type: Article

References (13)

1. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 2006, 130:323-333.
2. Colombel J.-F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., Pollack P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
3. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., Fedorak R.N., Lukas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., Li J., Pollack P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
4. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., D'Haens G., Li J., Rosenfeld M.R., Kent J.D., Pollack P.F. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007, 146:829-838.
5. ® [prescribing information] 2010, Abbott Laboratories, North Chicago, IL, Available at:, (accessed September 13, 2010). http://www.rxabbott.com/pdf/humira.pdf.
6. HUMIRA [summary of product characteristics] 2010, Abbott Laboratories Ltd., Berkshire, United Kingdom, Available at:, (accessed September 13, 2010). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf.
7. Sandborn W.J., Colombel J.-F., Schreiber S., Plevy S.E., Pollack P.F., Robinson A.M., Chao J., Mulani P. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17:141-151.
8. Russo E.A., Iacucci M., Lindsay J.O., Campbell S., Hart A., Hamlin J., Orchard T., Arebi N., Nightingale J., Jacyna M.R., Gabe S.M., O'Connor M., Harris A.W., O'Morain C., Ghosh S. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010, 22:334-339.
9. Ho G.T., Mowat A., Potts L., Cahill A., Mowat C., Lees C.W., Hare N.C., Wilson J.A., Boulton-Jones R., Priest M., Watts D.A., Shand A.G., Arnott I.D., Russell R.K., Wilson D.C., Morris A.J., Satsangi J. Efficacy and complications of adalimumab treatment for medically refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009, 29:527-534.
10. Swoger J.M., Loftus E.V., Tremaine W.J., Faubion W.A., Pardi D.S., Kane S.V., Hanson K.A., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010, 16:1912-1921.
11. Pan X., Zurawski P., Mulani P., Chao J. Adalimumab dosage increase in Crohn's disease in specialty pharmacies. J Manag Care Pharm 2009, 15:173.
12. Polsky D., Armstrong K.A., Randall T.C., Ross R.N., Even-Shoshan O., Rosenbaum P.R., Silber J.H. Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. Health Serv Res 2006, 41:2201-2218.
13. Swaminath A., Lebwohl B., Capiak K.M., Present D.H. Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts. Dig Dis Sci 2011, 56:1160-1164.